Navigation Links
Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
Date:4/4/2008

PRINCETON, N.J., April 4, 2008 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Canaccord|Adams Hepatitis C Conference being held on April 9, 2008 at the St. Regis Hotel in New York, NY. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company's clinical and preclinical hepatitis C virus (HCV) programs at 11:15 AM (ET).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, fo
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmasset Receives $10 Million of Working Capital
2. Pharmasset Appoints Herbert J. Conrad as a Director
3. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
4. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
5. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset Appoints Michael Rogers as Chief Development Officer
8. Pharmasset to Present at Three Investor Conferences in November 2007
9. Pharmasset Accesses up to $30 Million of Working Capital
10. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
11. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Freeslate, ... solutions, today announced that Lupin Limited, one of India’s ... CM Protégé PharmD System for high throughput ... India, is focused on a wide range of quality, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Tumors Associated ... with HER2-Positive Breast Cancer, SAN ANTONIO, Texas, Dec. ... a Phase II study on its,first-in-class, oral small molecule HER2 ... the combination of,TYKERB plus capecitabine (Xeloda(R)) showed a reduction in ...
... - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) and ... pharmaceutical and medical devices company, today,announced the ... System,in Germany. Celacade, a first-in-class therapy, is ... targets the destructive chronic,inflammation underlying the development ...
... Mednet, SWOG Will Enhance Quality and Speed Image Transfer at ... Cost While Ensuring 21 CFR Part 11 ... largest,diagnostic imaging network, today announced it has been selected by,Southwest ... trials cooperative groups in the United States, to provide a,secure, ...
Cached Biology Technology:GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 2GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 3GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 4GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 5GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 6Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 2Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 3Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 4Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 5AG Mednet to Provide Image Network for Southwest Oncology Group 2
(Date:4/21/2014)... lower cholesterol can reduce heart attack and stroke risk, ... save the vision of diabetics, scientists say. , In ... of niacin to decrease bad cholesterol levels and raise ... for these patients, said Dr. Pamela Martin, biochemist at ... , Martin is Principal Investigator on a new ...
(Date:4/20/2014)... 20, 2014) A team of researchers from ... College, and Brandeis University has devised a wholly ... involving the so-called retromer protein complex. Retromer plays ... protein (APP) away from a region of the ... toxic byproduct amyloid-beta, which is thought to contribute ...
(Date:4/20/2014)... Although doctors have long known that people with Down ... leukemia (ALL) during childhood, they haven,t been able to ... Institute investigators has uncovered a connection between the two ... the journal Nature Genetics , the researchers track ... abnormality in Down syndrome to the cellular havoc that ...
Breaking Biology News(10 mins):Scientists target receptor to treat diabetic retinopathy 2Scientists target receptor to treat diabetic retinopathy 3'Chaperone' compounds offer new approach to Alzheimer's treatment 2'Chaperone' compounds offer new approach to Alzheimer's treatment 3Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3
... La Jolla, CA - Salk Institute professor Terrence J. ... the neural networks revolution in computing in the 1980s, ... of Sciences. The Academy made the announcement today during ... the Academy recognizes distinguished and continuing achievements in original ...
... CARSON CITY, Nev. , April 27 State of ... by participating in The Prevention Plan™, a U.S. Preventive Medicine® program designed to ... before they progress. The program is projected to save Nevada ... , , ...
... , ATLANTA , April 27   Georgia Power received approval April 20 ... more solar options. , , , ... , , ... to include the following: , , , ...
Cached Biology News:Salk scientist Terrence Sejnowski elected to National Academy of Sciences 2U.S. Preventive Medicine Helps Participants of the State of Nevada Public Employees' Benefits Program (PEBP) Become Healthier 2U.S. Preventive Medicine Helps Participants of the State of Nevada Public Employees' Benefits Program (PEBP) Become Healthier 3Georgia Power's Green Energy Program Redesigned to Include More Solar Power 2
... advanced protein cross-linking techniques are defined by ... Shan S. Wong. This valuable hardcover guide ... and current application references. More than 300 ... cross-linking and conjugate preparation from selection ...
... The proteomic service includes protein separation ... using the PDQuest software package from ... mass spectrometry. In order to meet ... preparation, data analysis and format of ...
... provides reagents for immune complex disruption (ICD) ... samples using a combination of low pH ... and transferred to microplate wells which are ... antibody to HIV-1 p24. The immobilized monoclonal ...
... endotoxin-free plasmid DNA preparations are prepared ... quantities from 1mg to multi-gram scales. ... customer needs, and glycerol stocks are ... Transformation, clonal selection (Clonal selection includes ...
Biology Products: